Asset profile

Methotrexate

Unknown / undisclosed

ApprovedUndisclosed / early pipelineDihydrofolate reductase (DHFR)
Approvedregulatory verdict

Evidence outlook

Approved — Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (4)
September 2026 (3)
Phase 2Metastatic Breast Cancer, Leptomeningeal DiseaseRecruiting
Est. primary completion 2026-09 · NCT02422641 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Rheumatoid ArthritisActive not recruiting
Est. primary completion 2026-09-05 · NCT07176390 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Rheumatoid ArthritisActive not recruiting
Est. primary completion 2026-09-30 · NCT07008846 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 2Leptomeningeal Metastasis of Breast CancerRecruiting
Est. primary completion 2026-12-13 · NCT06543992 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (1)
January 2027 (1)
Phase 2Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2027-01-15 · NCT06590090 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
May 2029 (1)
Phase 2/3Rheumatoid ArthritisRecruiting
Est. primary completion 2029-05-31 · NCT07627893 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2034 (1)
September 2034 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2034-09 · NCT06085742 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.